Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high risk smoldering multiple myeloma included in the GEM-CESAR trial

The value of quantitative immunoprecipitation mass spectrometry (QIP-MS) to identify the M-protein is being investigated in patients with monoclonal gammopathies but no data are yet available in high-risk smoldering myeloma (HRsMM). We have therefore investigated QIP-MS to monitor peripheral residu...

Full description

Bibliographic Details

Published in:	Haematologica
Main Authors:	Noemí Puig, Cristina Agulló, Teresa Contreras, José-Juan Pérez, Irene Aires, María-José Calasanz, Ramón García-Sanz, Sergio Castro, Joaquín Martínez-López, Paula Rodríguez-Otero, Verónica González-Calle, Marta S González, Albert Oriol, Norma C Gutiérrez, Rafael Ríos-Tamayo, Laura Rosiñol, Miguel-Ángel Álvarez, Joan Bargay, Ana-Pilar González-Rodríguez, Adrián Alegre, Fernando Escalante, María-Belén Iñigo, Javier de la Rubia, Ana-Isabel Teruel, Felipe de Arriba, Luis Palomera, Miguel T Hernández, Javier López-Jiménez, Marta Reinoso, Aránzazu García-Mateo, Enrique M Ocio, Joan Bladé, Juan-José Lahuerta, María-Teresa Cedena, Bruno Paiva, Jesús F San Miguel, María-Victoria Mateos
Format:	Article
Language:	English
Published:	Ferrata Storti Foundation 2024-07-01
Online Access:	https://haematologica.org/article/view/11683